- Home
- ONCY vs EQ Comparison
ONCY vs EQ Comparison
Compare ONCY & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCY
- EQ
- Stock Information
- Founded
- ONCY 1998
- EQ 2017
- Country
- ONCY Canada
- EQ United States
- Employees
- ONCY N/A
- EQ N/A
- Industry
- ONCY Pharmaceuticals and Biotechnology
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- ONCY Health Care
- EQ Health Care
- Exchange
- ONCY Nasdaq
- EQ Nasdaq
- Market Cap
- ONCY 89.7M
- EQ 85.1M
- IPO Year
- ONCY 1999
- EQ 2018
- Fundamental
- Price
- ONCY $1.20
- EQ $1.34
- Analyst Decision
- ONCY Strong Buy
- EQ Hold
- Analyst Count
- ONCY 5
- EQ 2
- Target Price
- ONCY $5.00
- EQ $1.00
- AVG Volume (30 Days)
- ONCY 1.0M
- EQ 725.3K
- Earning Date
- ONCY 11-11-2025
- EQ 11-12-2025
- Dividend Yield
- ONCY N/A
- EQ N/A
- EPS Growth
- ONCY N/A
- EQ N/A
- EPS
- ONCY N/A
- EQ N/A
- Revenue
- ONCY N/A
- EQ $16,553,000.00
- Revenue This Year
- ONCY N/A
- EQ N/A
- Revenue Next Year
- ONCY N/A
- EQ N/A
- P/E Ratio
- ONCY N/A
- EQ N/A
- Revenue Growth
- ONCY N/A
- EQ N/A
- 52 Week Low
- ONCY $0.33
- EQ $0.27
- 52 Week High
- ONCY $1.51
- EQ $2.35
- Technical
- Relative Strength Index (RSI)
- ONCY 44.08
- EQ 43.10
- Support Level
- ONCY $1.20
- EQ $1.41
- Resistance Level
- ONCY $1.47
- EQ $1.64
- Average True Range (ATR)
- ONCY 0.08
- EQ 0.11
- MACD
- ONCY -0.02
- EQ -0.02
- Stochastic Oscillator
- ONCY 3.23
- EQ 9.11
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.